Results 61 to 70 of about 2,000,472 (360)

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death [PDF]

, 2017
Although inhibition of the epidermal growth factor receptor is a plausible therapy for malignant gliomas that, in vitro, enhances apoptosis, the results of clinical trials have been disappointing.
Brucker, Daniel P., Burger, Michael C., Rieger, Johannes, Ronellenfitsch, Michael W., Steinbach, Joachim P., Tritschler, Felix, Weller, Michael, Wick, Wolfgang, Wolking, Stefan   +8 more
core  

Master regulators of FGFR2 signalling and breast cancer risk. [PDF]

, 2013
The fibroblast growth factor receptor 2 (FGFR2) locus has been consistently identified as a breast cancer risk locus in independent genome-wide association studies. However, the molecular mechanisms underlying FGFR2-mediated risk are still unknown. Using
Caldas, Carlos, Castro, Mauro AA, Chin, Suet-Feung, de Santiago, Ines, Fletcher, Michael NC, Markowetz, Florian, Meyer, Kerstin B, O'Reilly, Martin, Ponder, Bruce AJ, Rueda, Oscar M, Wang, Xin   +10 more
core   +2 more sources

Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide

International Journal of Nanomedicine, 2014
Khaled Messaoudi,1 Patrick Saulnier,1 Kim Boesen,1 Jean-Pierre Benoit,1,2 Frederic Lagarce1,21L'Université Nantes Angers Le Mans, INSERM U1066, Micro et nanomédecines biomimétiques, Angers, France; 2Pharmacy Department, Angers ...
Messaoudi K, Saulnier P, Boesen K, Benoit JP, Lagarce F   +4 more
doaj  

Research progress in targeted therapy for gastric cancer

Zhongguo linchuang yanjiu
Gastric cancer is a common malignant tumor worldwide, and its incidence rate and mortality have always been in the forefront. Most gastric cancer patients in China are diagnosed in the middle or late stages, with an unsatisfactory 5- year survival rate ...
WU Tengfei*, ZHAO Jinjin, LIN Jianxiu, TIAN Yun
doaj   +1 more source

Effects of EGFR Expression on Anti-tumor Efficacy of Vandetanib or Cediranib Combined with Radiotherapy (RT) in U87 Human Glioblastoma (GBM) Xenografts [PDF]

, 2010
Introduction: Vandetanib is a receptor tyrosine kinase inhibitor (RTKI) with activity against vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR).
Dicker, A. P., Lawrence, Y. R., Liu, Y., Wachsberger, P.   +3 more
core   +2 more sources

Exercise Interventions in Children, Adolescents and Young Adults With Paediatric Bone Tumours—A Systematic Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Bone tumours present significant challenges for affected patients, as multimodal therapy often leads to prolonged physical limitations. This is particularly critical during childhood and adolescence, as it can negatively impact physiological development and psychosocial resilience.
Jennifer Queisser, Claire Laurie, Teresa Schmidt, Irene von Luettichau, Peter Bekkering, Sabine Kesting   +5 more
wiley   +1 more source

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Tumor Biology, 2017
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj   +1 more source

Anti-Angiogenic Treatment (Sunitinib) for Disseminated Malignant Haemangiopericytoma: A Case Study and Review of the Literature

Case Reports in Oncology, 2011
Introduction: A meningeal haemangiopericytoma (HP) is a mesenchymal tumour that makes up less than 1% of all CNS tumours. HPs arise from pericytes and present high rates of recurrence and distant metastasis. The primary treatment option is surgery.
M. Delgado, E. Pérez-Ruiz, J. Alcalde, D. Pérez, R. Villatoro, A. Rueda   +5 more
doaj   +1 more source

The basic biology of erbB-2 and its participation in colorectal cancers [PDF]

, 2005
ErbB-2 is one of Tour cell surface growth factor receptors involved in transmission of signals controlling normal cell growth and differentiation. A range of growth factors serve as ligands, but none is specific for the ErbB-2 receptor.
Bryś, Magdalena, Krajewska, Wanda M., Stawińska, Magdalena   +2 more
core  

Positive and negative regulation of angiogenesis by soluble vascular endothelial growth factor receptor-1 [PDF]

, 2018
Vascular endothelial growth factor receptor (VEGFR)-1 exists in different forms, derived from alternative splicing of the same gene. In addition to the transmembrane form, endothelial cells produce a soluble VEGFR-1 (sVEGFR-1) isoform, whereas non ...
Carbo, Miriam, Failla, Cristina M., Morea, Veronica   +2 more
core   +2 more sources